Related Experiment Videos
Cefetamet pivoxil in acute pyelonephritis: an open study
C Stathakis1, N Roulleau, M Libert
1Nephrology Division, Laiko General Hospital, Athens, Greece.
Current Medical Research and Opinion
|January 1, 1990
Summary
Cefetamet pivoxil demonstrated a higher success rate in treating acute uncomplicated pyelonephritis compared to cefadroxil. This antibiotic showed faster symptom relief and fewer relapses, indicating improved therapeutic outcomes for patients.
Area of Science:
- Urology
- Infectious Diseases
- Pharmacology
Background:
- Acute uncomplicated pyelonephritis is a common kidney infection.
- Effective antibiotic treatment is crucial for preventing complications.
Purpose of the Study:
- To compare the efficacy and tolerability of cefetamet pivoxil versus cefadroxil in treating acute uncomplicated pyelonephritis.
Main Methods:
- An open, prospective, randomized comparative study.
- 55 adult patients with acute uncomplicated pyelonephritis.
- Cefetamet pivoxil (1000 mg twice daily) vs. cefadroxil (1000 mg twice daily) for 10-15 days.
Main Results:
- Cefetamet pivoxil showed more rapid subsidence of clinical signs and symptoms.
- Sterile urine achieved in 100% of cefetamet pivoxil patients vs. 93.6% of cefadroxil patients at treatment end.
- Overall therapeutic success was 89.7% for cefetamet pivoxil vs. 72.7% for cefadroxil.
- Relapse rates were 13.8% for cefetamet pivoxil and 13.6% for cefadroxil at follow-up.
Conclusions:
- Cefetamet pivoxil is an effective oral treatment for acute uncomplicated pyelonephritis with a higher success rate than cefadroxil.
- Both drugs were well-tolerated with mild to moderate adverse events.